Considerations of Quality Control Issues for the Mesenchymal Stem Cells-Based Medicinal Products

Bao Zhu Yuan, Debanjan Sarkar, Simone Pacini, Mahmood Khan, Miodrag Stojkovic, Martin Zenke, Richard Boyd, Armand Keating, Eric Raymond, Robert Chunhua Zhao

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Otherpeer-review

Abstract

Mesenchymal stem cells (MSCs) represent a potentially attractive product for achieving successful stem-cell-based therapy. Clinical application studies of the MSCs for a variety of diseases such as graft-versus-host disease, liver fibrosis, heart disease, diabetes, osteoarthritis, and spinal cord injury have been proposed worldwide. While clinical applications of MSC-based therapy (MSCT) increasingly gain popularity among clinical practitioners and researchers, concerns have been raised on quality issues of MSCs among all stem cell-based medicinal products (SCMP). Quality issues are associated with donor's qualification and in vitro cell processing as well as some still unknown biological characteristics of the MSCs, especially in the context of potential tumorigenicity. Quality issues could affect safety and efficacy of the MSCT. To ensure optimal quality assurance for both safety and efficacy of the stem cell-based therapy in clinical trials, processes for SCMP production, quality control tests are necessary at each step. More specifically, donor identity, stem cell tissue origins, purity, safety, potency, and stability, must be strictly controlled during the entire product development cycle.

Original languageEnglish
Title of host publicationEssentials of Mesenchymal Stem Cell Biology and Its Clinical Translation
PublisherSpringer
Pages265-278
Number of pages14
ISBN (Electronic)9789400767164
ISBN (Print)9789400767157
DOIs
Publication statusPublished - 1 Jan 2013

Keywords

  • Medical product
  • MSC
  • Quality control

Cite this

Yuan, B. Z., Sarkar, D., Pacini, S., Khan, M., Stojkovic, M., Zenke, M., ... Zhao, R. C. (2013). Considerations of Quality Control Issues for the Mesenchymal Stem Cells-Based Medicinal Products. In Essentials of Mesenchymal Stem Cell Biology and Its Clinical Translation (pp. 265-278). Springer. https://doi.org/10.1007/978-94-007-6716-4_18
Yuan, Bao Zhu ; Sarkar, Debanjan ; Pacini, Simone ; Khan, Mahmood ; Stojkovic, Miodrag ; Zenke, Martin ; Boyd, Richard ; Keating, Armand ; Raymond, Eric ; Zhao, Robert Chunhua. / Considerations of Quality Control Issues for the Mesenchymal Stem Cells-Based Medicinal Products. Essentials of Mesenchymal Stem Cell Biology and Its Clinical Translation. Springer, 2013. pp. 265-278
@inbook{f35d86721f7e4663b6e20c4105a1ee21,
title = "Considerations of Quality Control Issues for the Mesenchymal Stem Cells-Based Medicinal Products",
abstract = "Mesenchymal stem cells (MSCs) represent a potentially attractive product for achieving successful stem-cell-based therapy. Clinical application studies of the MSCs for a variety of diseases such as graft-versus-host disease, liver fibrosis, heart disease, diabetes, osteoarthritis, and spinal cord injury have been proposed worldwide. While clinical applications of MSC-based therapy (MSCT) increasingly gain popularity among clinical practitioners and researchers, concerns have been raised on quality issues of MSCs among all stem cell-based medicinal products (SCMP). Quality issues are associated with donor's qualification and in vitro cell processing as well as some still unknown biological characteristics of the MSCs, especially in the context of potential tumorigenicity. Quality issues could affect safety and efficacy of the MSCT. To ensure optimal quality assurance for both safety and efficacy of the stem cell-based therapy in clinical trials, processes for SCMP production, quality control tests are necessary at each step. More specifically, donor identity, stem cell tissue origins, purity, safety, potency, and stability, must be strictly controlled during the entire product development cycle.",
keywords = "Medical product, MSC, Quality control",
author = "Yuan, {Bao Zhu} and Debanjan Sarkar and Simone Pacini and Mahmood Khan and Miodrag Stojkovic and Martin Zenke and Richard Boyd and Armand Keating and Eric Raymond and Zhao, {Robert Chunhua}",
year = "2013",
month = "1",
day = "1",
doi = "10.1007/978-94-007-6716-4_18",
language = "English",
isbn = "9789400767157",
pages = "265--278",
booktitle = "Essentials of Mesenchymal Stem Cell Biology and Its Clinical Translation",
publisher = "Springer",

}

Yuan, BZ, Sarkar, D, Pacini, S, Khan, M, Stojkovic, M, Zenke, M, Boyd, R, Keating, A, Raymond, E & Zhao, RC 2013, Considerations of Quality Control Issues for the Mesenchymal Stem Cells-Based Medicinal Products. in Essentials of Mesenchymal Stem Cell Biology and Its Clinical Translation. Springer, pp. 265-278. https://doi.org/10.1007/978-94-007-6716-4_18

Considerations of Quality Control Issues for the Mesenchymal Stem Cells-Based Medicinal Products. / Yuan, Bao Zhu; Sarkar, Debanjan; Pacini, Simone; Khan, Mahmood; Stojkovic, Miodrag; Zenke, Martin; Boyd, Richard; Keating, Armand; Raymond, Eric; Zhao, Robert Chunhua.

Essentials of Mesenchymal Stem Cell Biology and Its Clinical Translation. Springer, 2013. p. 265-278.

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Otherpeer-review

TY - CHAP

T1 - Considerations of Quality Control Issues for the Mesenchymal Stem Cells-Based Medicinal Products

AU - Yuan, Bao Zhu

AU - Sarkar, Debanjan

AU - Pacini, Simone

AU - Khan, Mahmood

AU - Stojkovic, Miodrag

AU - Zenke, Martin

AU - Boyd, Richard

AU - Keating, Armand

AU - Raymond, Eric

AU - Zhao, Robert Chunhua

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Mesenchymal stem cells (MSCs) represent a potentially attractive product for achieving successful stem-cell-based therapy. Clinical application studies of the MSCs for a variety of diseases such as graft-versus-host disease, liver fibrosis, heart disease, diabetes, osteoarthritis, and spinal cord injury have been proposed worldwide. While clinical applications of MSC-based therapy (MSCT) increasingly gain popularity among clinical practitioners and researchers, concerns have been raised on quality issues of MSCs among all stem cell-based medicinal products (SCMP). Quality issues are associated with donor's qualification and in vitro cell processing as well as some still unknown biological characteristics of the MSCs, especially in the context of potential tumorigenicity. Quality issues could affect safety and efficacy of the MSCT. To ensure optimal quality assurance for both safety and efficacy of the stem cell-based therapy in clinical trials, processes for SCMP production, quality control tests are necessary at each step. More specifically, donor identity, stem cell tissue origins, purity, safety, potency, and stability, must be strictly controlled during the entire product development cycle.

AB - Mesenchymal stem cells (MSCs) represent a potentially attractive product for achieving successful stem-cell-based therapy. Clinical application studies of the MSCs for a variety of diseases such as graft-versus-host disease, liver fibrosis, heart disease, diabetes, osteoarthritis, and spinal cord injury have been proposed worldwide. While clinical applications of MSC-based therapy (MSCT) increasingly gain popularity among clinical practitioners and researchers, concerns have been raised on quality issues of MSCs among all stem cell-based medicinal products (SCMP). Quality issues are associated with donor's qualification and in vitro cell processing as well as some still unknown biological characteristics of the MSCs, especially in the context of potential tumorigenicity. Quality issues could affect safety and efficacy of the MSCT. To ensure optimal quality assurance for both safety and efficacy of the stem cell-based therapy in clinical trials, processes for SCMP production, quality control tests are necessary at each step. More specifically, donor identity, stem cell tissue origins, purity, safety, potency, and stability, must be strictly controlled during the entire product development cycle.

KW - Medical product

KW - MSC

KW - Quality control

UR - http://www.scopus.com/inward/record.url?scp=84955741232&partnerID=8YFLogxK

U2 - 10.1007/978-94-007-6716-4_18

DO - 10.1007/978-94-007-6716-4_18

M3 - Chapter (Book)

SN - 9789400767157

SP - 265

EP - 278

BT - Essentials of Mesenchymal Stem Cell Biology and Its Clinical Translation

PB - Springer

ER -

Yuan BZ, Sarkar D, Pacini S, Khan M, Stojkovic M, Zenke M et al. Considerations of Quality Control Issues for the Mesenchymal Stem Cells-Based Medicinal Products. In Essentials of Mesenchymal Stem Cell Biology and Its Clinical Translation. Springer. 2013. p. 265-278 https://doi.org/10.1007/978-94-007-6716-4_18